Literature DB >> 32352272

mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1).

Golnaz Kamalinia1, Brian J Engel2, Anupallavi Srinivasamani3, Brian J Grindel2, Justin N Ong4, Michael A Curran3, Terry T Takahashi1, Steven W Millward2, Richard W Roberts1,4,5.   

Abstract

Programmed death ligand 1 (PD-L1) is a critical immune checkpoint ligand whose overexpression on tumor cells provides a mechanism of escape from immune surveillance. The interaction between PD-L1 and PD-1 on T cell lymphocytes suppresses both T cell activation and effector function and is engaged by cancers to dampen antitumor immunity. Here, we used mRNA display to engineer an 18-residue linear peptide that binds to human PD-L1. This peptide, which we term SPAM (signal peptide-based affinity maturated ligand), is nonhomologous to known PD-L1 binding peptides and mAbs, with dissociation constants (KD) of 119 and 67 nM for unglycosylated and glycosylated human PD-L1, respectively. The SPAM peptide is highly selective for human PD-L1 and shows no significant binding to either mouse PD-L1 or human PD-L2. Competition binding assays indicate that the SPAM peptide binding site overlaps with the binding site of PD-1 as well as therapeutic anti-PD-L1 antibodies. Taken together, these results suggest that the SPAM peptide specifically binds to human PD-L1 and could potentially serve as a PD-L1 affinity agent and PD-L1/PD-1 pathway modulator.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32352272      PMCID: PMC7416570          DOI: 10.1021/acschembio.0c00264

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  52 in total

1.  A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation.

Authors:  D Beckett; E Kovaleva; P J Schatz
Journal:  Protein Sci       Date:  1999-04       Impact factor: 6.725

Review 2.  mRNA display: ligand discovery, interaction analysis and beyond.

Authors:  Terry T Takahashi; Ryan J Austin; Richard W Roberts
Journal:  Trends Biochem Sci       Date:  2003-03       Impact factor: 13.807

Review 3.  PD-1 signaling in primary T cells.

Authors:  James L Riley
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

4.  Pembrolizumab for the treatment of non-small-cell lung cancer.

Authors:  Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

5.  Coupling of monoclonal antibodies with fluorophores.

Authors:  R P Haugland
Journal:  Methods Mol Biol       Date:  1995

6.  Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.

Authors:  Lisa Zimmer; Simone M Goldinger; Lars Hofmann; Carmen Loquai; Selma Ugurel; Ioannis Thomas; Maria I Schmidgen; Ralf Gutzmer; Jochen S Utikal; Daniela Göppner; Jessica C Hassel; Friedegund Meier; Julia K Tietze; Andrea Forschner; Carsten Weishaupt; Martin Leverkus; Renate Wahl; Ursula Dietrich; Claus Garbe; Michael C Kirchberger; Thomas Eigentler; Carola Berking; Anja Gesierich; Angela M Krackhardt; Dirk Schadendorf; Gerold Schuler; Reinhard Dummer; Lucie M Heinzerling
Journal:  Eur J Cancer       Date:  2016-04-13       Impact factor: 9.162

Review 7.  A review of serious adverse effects under treatment with checkpoint inhibitors.

Authors:  Lucie Heinzerling; Simone M Goldinger
Journal:  Curr Opin Oncol       Date:  2017-03       Impact factor: 3.645

8.  Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.

Authors:  Katarzyna Magiera-Mularz; Lukasz Skalniak; Krzysztof M Zak; Bogdan Musielak; Ewa Rudzinska-Szostak; Łukasz Berlicki; Justyna Kocik; Przemyslaw Grudnik; Dominik Sala; Tryfon Zarganes-Tzitzikas; Shabnam Shaabani; Alexander Dömling; Grzegorz Dubin; Tad A Holak
Journal:  Angew Chem Int Ed Engl       Date:  2017-09-26       Impact factor: 15.336

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

10.  Serum stable natural peptides designed by mRNA display.

Authors:  Shannon M Howell; Stephen V Fiacco; Terry T Takahashi; Farzad Jalali-Yazdi; Steven W Millward; Biliang Hu; Pin Wang; Richard W Roberts
Journal:  Sci Rep       Date:  2014-09-19       Impact factor: 4.379

View more
  3 in total

Review 1.  Peptides that immunoactivate the tumor microenvironment.

Authors:  Natsuki Furukawa; Aleksander S Popel
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-12-01       Impact factor: 10.680

Review 2.  Directing evolution of novel ligands by mRNA display.

Authors:  Golnaz Kamalinia; Brian J Grindel; Terry T Takahashi; Steven W Millward; Richard W Roberts
Journal:  Chem Soc Rev       Date:  2021-06-24       Impact factor: 60.615

3.  Expanding the Chemical Diversity of Genetically Encoded Libraries.

Authors:  Sabrina E Iskandar; Victoria A Haberman; Albert A Bowers
Journal:  ACS Comb Sci       Date:  2020-11-09       Impact factor: 3.903

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.